Dipexium Pharmaceuticals CEO Natasha Giordano's 2019 pay jumps 162% to $1.6M
Dipexium Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: September 25, 2020
Dipexium Pharmaceuticals reported fiscal year 2019 executive compensation information on September 25, 2020.
In 2019, four executives at Dipexium Pharmaceuticals received on average a compensation package of $1M, a 129% increase compared to previous year.
Average pay of disclosed executives at Dipexium Pharmaceuticals
Natasha Giordano, Chief Executive Officer, received $1.6M in total, which increased by 162% compared to 2018. 54% of Giordano's compensation, or $866K, was in option awards. Giordano also received $265K in non-equity incentive plan, $469K in salary, as well as $16K in other compensation.
Rita M. O'Connor, Chief Financial Officer, received a compensation package of $1.1M, which increased by 129% compared to previous year. 48% of the compensation package, or $506K, was in option awards.
Efthymios Deliargyris, Chief Medical Officer, earned $802K in 2019, a 85% increase compared to previous year.
Michael J. Valentino, Chairman, received $680K in 2019, which increases by 127% compared to 2018.
Related executives
You may also like
Source: SEC filing on September 25, 2020.